A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- Conditions
- Refractory B-Cell NHLRelapsed B-cell NHLLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06470438
- Locations
- ๐จ๐ณ
Sun Yat Sen University Cancer Center, Guangzhou, China
๐จ๐ณBeijing Cancer Hospital, Beijing, China
๐จ๐ณThe First Affiliated Hospital Zhejiang University College of Medicine, Hang Zhou Shi, China
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Conditions
- Thrombocytopenia, Neonatal Alloimmune
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT06449651
- Locations
- ๐ซ๐ท
CHRU Lille, Lille, France
๐ซ๐ทHopital trousseau- APHP, Paris, France
๐ญ๐บSemmelweis Egyetem, Budapest, Hungary
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT06425991
- Locations
- ๐บ๐ธ
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
๐บ๐ธColorado Blood Cancer Institute, Denver, Colorado, United States
๐บ๐ธCleveland Clinic Florida, Weston, Florida, United States
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
- Conditions
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 247
- Registration Number
- NCT06385080
- Locations
- ๐บ๐ธ
University of Colorado Denver Anschultz Medical Campus, Aurora, Colorado, United States
๐จ๐ณFudan Cancer Hospital, ShangHai, China
๐บ๐ธUniversity of California at San Diego Moores Cancer Center, La Jolla, California, United States
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 540
- Registration Number
- NCT06319820
- Locations
- ๐ฎ๐ช
Adelaide and Meath Hospital, Dublin, Ireland
๐ฐ๐ทNational Cancer Center, Gyeonggi-do, Korea, Republic of
๐ฐ๐ทChonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06260163
- Locations
- ๐บ๐ธ
Children's Hospital Oakland, Oakland, California, United States
๐บ๐ธRiley Hospital for Children, Indianapolis, Indiana, United States
๐บ๐ธNYU Langone Health, Lake Success, New York, United States
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06255665
- Locations
- ๐ช๐ธ
Hosp Univ Vall D Hebron, Barcelona, Spain
๐ช๐ธHosp Univ Fund Jimenez Diaz, Madrid, Spain
๐ช๐ธHosp Univ Hm Sanchinarro, Madrid, Spain
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- Conditions
- Plaque Psoriasis
- Interventions
- Drug: JNJ-77242113 Matching Placebo
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 731
- Registration Number
- NCT06220604
- Locations
- ๐ฉ๐ช
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
๐ต๐ฑWroMedica I Bielicka A Strzalkowska s c, Wroclaw, Poland
๐บ๐ธEssential Medical Research, Tulsa, Oklahoma, United States
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guรฉrin (BCG)
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06211764
- Locations
- ๐ฎ๐น
Universita Campus Bio-Medico di Roma, Roma, Italy
๐ฎ๐นIstituto Nazionale Tumori Regina Elena, Roma, Italy
๐ฎ๐นIstituto Clinico Humanitas, Rozzano, Italy
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- ๐ธ๐ช
Akademiska Sjukhuset, Uppsala, Sweden
๐ธ๐ชVarberg Hospital, Varberg, Sweden
๐บ๐ธUCSF Fresno, Clovis, California, United States